ChrysCapital Acquires Minority Stake in La Renon

Ren Receives Strategic Growth Investment from Bain Capital Tech Opportunities and Valeas Capital Partners

July 26, 2023

Cloud & SaaS

Ren, an Indianapolis-based provider of donor-advised fund enablement software and services, received a strategic growth investment led by Bain Capital Tech Opportunities and Valeas Capital Partners. The capital — Ren's first institutional funding — will be used to build new product features, rapidly scale the team, increase advisor and client awareness of donor-advised funds, and expand Ren's charity network; financial terms were not disclosed. Raymond James acted as exclusive financial advisor.

Chugai Pharmaceutical to Acquire Renalys Pharma

October 24, 2025

Biotechnology

Chugai Pharmaceutical Co., Ltd. will acquire Renalys Pharma, Inc. through a definitive stock purchase agreement. The transaction includes an upfront payment of JPY 15.0 billion and potential earn-outs of up to JPY 16.0 billion tied to regulatory and sales milestones for sparsentan in Japan, South Korea, and Taiwan.

Chardan Healthcare Acquisition 2 Corp. Completes Business Combination with Renovacor, Inc.

September 2, 2021

Biotechnology

Renovacor, an early‑stage biotechnology company developing AAV‑based gene therapies for BAG3‑associated cardiovascular and CNS diseases, closed a business combination with special purpose acquisition company Chardan Healthcare Acquisition 2 Corp. (CHAQ) and will begin trading on the New York Stock Exchange as Renovacor, Inc., with approximately $95.1 million of gross proceeds (including a $30.0 million PIPE) to fund clinical development into 2023. The transaction preserves Renovacor’s existing management team and provides public-market access and capital to advance its lead program, REN‑001, toward IND submission and a Phase I/II trial.

Fremman Capital Acquires Majority Stake in rehaneo from Gimv

November 20, 2024

Healthcare Services

Fremman Capital has agreed to acquire a majority stake in German outpatient rehabilitation group rehaneo from European investment company Gimv. The founders Bruno Crone and Christoph Dühr remain significant shareholders and will continue to run the business; the deal is subject to German antitrust approval and is expected to close in Q1 2025.

Pharos Capital Invests in Renal Care 360°

September 1, 2022

Healthcare Services

Pharos Capital Group made a significant growth investment in Renal Care 360°, a nephrology practice and chronic kidney disease management company led by founder Joe Cashia. The capital (terms undisclosed) will support scaling the RC360° Connected Care Program, geographic expansion through acquisitions, and development of value-based care capabilities while Mr. Cashia remains Chairman and CEO.

Lupin Healthcare Acquires Renascience Pharma Limited (UK)

April 2, 2025

Pharmaceuticals

Lupin Healthcare (UK) Limited, a wholly owned subsidiary of Lupin Limited, has acquired UK-based Renascience Pharma Limited, the sole supplier of four specialty branded products in the UK. The acquisition (reported at approximately £12.3 million) expands Lupin's branded specialty portfolio in the UK and strengthens its supply offerings to the NHS across infectious disease, ENT and cardiology/renal indications.